Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

Xếp hạng trong cổ phiếu #2200
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Giá cổ phiếu
$139.30
Vốn hóa thị trường
$9.01B
Thay đổi (1 ngày)
0.88%
Thay đổi (1 năm)
89.52%
Quốc gia
US
Giao dịch Protagonist Therapeutics, Inc. (PTGX)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Protagonist Therapeutics, Inc. (PTGX)
Giá đóng cửa cao nhất: $138.62 vào 2026-10-01

Giá đóng cửa thấp nhất: $11.34 vào 2016-08-01
Lịch sử giá cổ phiếu của Protagonist Therapeutics, Inc. từ 2016 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 21.88%
2025 119.26%
2024 92.93%
2023 131.51%
2022 -72.05%
2021 46.48%
2020 203.82%
2019 9.00%
2018 -65.01%
2017 -15.57%
2016 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $533.52 25.11%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $183.54 583.58%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $137.83 -3.78%
AU
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $291.76 2.51%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $887.97 9.06%
NL